Drugs targeting the central nervous system take significantly longer to develop and get approved than other meds, according to a new analysis. In fact, the report cites that CNS drugs took 20% longer to develop and about 19 months (36%) longer on average than other meds to win FDA approval after clinical trials.
Benchmark your study enrollment versus competitorsGet Benchmark Data
Other content in this Stream
Invert to Convert: Rethinking Patient Recruitment and Enrollment Strategies
Infograph: Rethinking Patient Recruitment
Despite advances in science, medicine and tech, 90% of clinical trials struggle to meet enrollment. We propose flipping the funnel to address site resourcing issue and convert recruits into enrollees.
Solving the Problem of Clinical Research Enrollment
Six Practices of High Performing Clinical Research Sites
Learn what high-performing research sites have in common, and what makes sponsors return to them again and again.
Q&A with CNS Expert, Dr. Leslie Citrome
Leslie Citrome, MD, MPH, a member of WCG’s Scientific Leadership Team, shared his insights during a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
Recruiting Patients & Time Management: Top Tips for Dealing with the Most Critical Resource in Research
Learn how to engage sites more effectively with the appropriate recruitment resources, use dedicated staff to manage recruitment efforts, and eliminate bottlenecks and expedite recruitment timelines.
Q&A with CNS Expert, Dr. Christoph U. Correll
Christoph U. Correll, MD, a member of WCG’s Scientific Leadership Team, shared his thoughts in a recent conversation with Mark Opler, MD, PhD, chief research officer at WCG-MedAvante-ProPhase.
Trend: Genetic Testing and Data Privacy Ownership
Interview with Dr. Leslie Citrome
Interview with Dr. Cristoph Correll
Christoph Correll, MD, a member of WCG’s Scientific Leadership Team, shares his thoughts on the most important trends in CNS clinical trials and what lies ahead in 2019
Clinical Trial Recruitment Practices: The Evolution of Ethical Considerations
Subject Recruitment Materials: Understanding the Requirements for IRB Review
Often, the only way for potential research subjects to learn about a clinical trial is through recruitment materials. But what materials must you submit to the IRB for review?
eCOA: Keep it Simple, Exec Argues
Nearly half of all clinical trials still use paper as the primary - or even sole - source of records while barely a quarter of trials use eCOA or ePRO
Clinical Trials and Social Media - Friends or Foes?
Rare Disease Case Study: Pediatric Sickle Cell Anemia
Our client, a Top 10 pharmaceutical company, needed to boost enrollment for their phase ll pediatric sickle cell anemia study.
Rare & Orphan Disease Endpoints: Challenges & Examples from Neurodevelopment
Personalized Medicine Requires Personalized Measurement
How we measure outcomes will evolve from applying one solution to finding an empirical basis for a highly customized application of all of them, enabled by technology
Patient Engagement Services Overview
Patient Recruitment for Ophthalmology Study (Glaucoma and Retinal Disease)
A leading pharma company needed assistance to rescue their enrolling ophthalmology study. The sponsor was attempting to complete enrollment for a normative, glaucoma and retinal disease study.
Patient Recruitment for Multi-Protocol Global Program (Phase III Cardiovascular Disease)